Given the emerging relevance of HDAC inhibition in reshaping anti-tumor immunity, future work should incorporate immune-competent models to evaluate the potential immunomodulatory impact of MS275 in hepatocellular carcinoma. This evidence concerns the gene HDAC9 and neoplasm.